Dr. Shikha Mittoo MD, MHS, FRCP(C) (Rheumatology)
Assistant Professor, Department of Medicine, Division of Rheumatology and Mount Sinai Hospital/University Health Network Interstitial Lung Disease Program
Lung disease occurs in approximately 30 – 50% of patients with a connective tissue disorder (rheumatoid arthritis, idiopathic inflammatory myositis, lupus, scleroderma, Sjogren’s) during the course of the disease and, depending on the type of lung condition, is associated with increased mortality. Emerging date suggests that early events leading to autoimmunity and development of conditions, such as rheumatoid arthritis and myositis may occur in the respiratory tract. Dr. Mittoo’s clinical interests are related to the management of rheumatoid arthritis and rheumatoid arthritis lung disease.
Her research interest is focused on studying the impact of lung disease on clinical outcomes of patients with a rheumatic disease. Specifically, during her fellowship in rheumatology and Master’s in Clinical Investigation, Dr. Mittoo studied the role of serum and airway biomarkers in predicting poor clinical outcomes among patients with scleroderma. She has since expaned her clinical care and research to lupus lung disease and rheumatoid interstitial lung disease and is serving as the co-research director for the Lung Disease program at MSH/UHN.
Dr. Mittoo is an Adjunct Assistant Professor at the University of Toronto and has more than 10 years of academic experience and research experience across various inflammatory diseases. She has nearly 15 years of clinical experience in rheumatology (Fellowship was 2015 to preset). Since 2013 she has been the primary teaching preceptor for the Mount Sinai Hospital family medicine trainee program and is currently the York University preceptor for the teaching nurse practitioner program. Since mid-2018 she has been a Peer Assessor in the field of rheumatology, for the College of Physicians and Surgeons. Dr. Mittoo is a Staff Rheumatologist for the University Health Network (UHN).